Drug Profile
Alemtuzumab biosimilar - BioXpress Therapeutics
Alternative Names: BX 1523; BXT-1523Latest Information Update: 05 Dec 2022
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD52 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chronic lymphocytic leukaemia
Most Recent Events
- 05 Dec 2022 Alemtuzumab biosimilar is still in preclinical development in Chronic-lymphocytic-leukaemia in Switzerland (IV, Infusion) (BioXpress Therapeutics pipeline, December 2022)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Switzerland (IV, Infusion)
- 29 Aug 2019 Alemtuzumab biosimilar is still in preclinical development in Chronic-lymphocytic-leukaemia in Switzerland (IV, Infusion)